Drugs.com - Clinical Trials

Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia

Newton, MA, February 24, 2025 – Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient out comes in oncology and inflammatory disease, today announced that the U.S. Food and Drug...

Feb 26, 2025 - 02:24
 0
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
Newton, MA, February 24, 2025 – Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient out comes in oncology and inflammatory disease, today announced that the U.S. Food and Drug...
Read More

Tags:

Previous Article

QOTD: Why Aren't There More E-REVs on the Road?

Next Article

Axon CEO riffs on HQ uncertainty as shares pop amid strong earnings

Related Posts

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Po...

Feb 9, 2025  0

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

Annovis Announces First Patients Entered into Pivotal P...

Feb 9, 2025  0

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Receives Fast Track Designation for...

Feb 10, 2025  0